Please login to the form below

Not currently logged in
Email:
Password:

epigenetics

This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.

BMS’ oral maintenance therapy boosts survival in AML patients

BMS’ oral maintenance therapy boosts survival in AML patients

We are extremely encouraged by the results of the QUAZAR AML-001 study as a part of our continuing commitment to both epigenetic research and myeloid diseases,” said Samit Hariwat, chief

Latest news

  • RNA-focused biotech Storm Therapeutics raises extra £14m RNA-focused biotech Storm Therapeutics raises extra £14m

    First set up in 2015 by epigenetics and RNA specialists Professor Tony Kouzarides and Professor Eric Miska, the Cambridge-based company has a pipeline of early-stage molecules in development in ... world-leading company harnessing the power of RNA

  • Researchers reverse Alzheimer’s memory loss in mice Researchers reverse Alzheimer’s memory loss in mice

    The Buffalo researchers believe their work in the developing science of epigenetics will yield answers in the elusive search for new Alzheimer's therapies. ... The researchers found that the loss of glutamate receptors resulted from an epigenetic process

  • GSK: we won’t be splitting up any time soon GSK: we won’t be splitting up any time soon

    Particularly in the spotlight is oncology, where GSK has cell therapy candidates, epigenetic modulators and antibodies targeting immune cells.

  • AstraZeneca to explore link between epigenetics and respiratory diseases AstraZeneca to explore link between epigenetics and respiratory diseases

    Epigenetics are changes in the expression of genes attributed to lifestyle factors affecting the body, but do not alter the DNA sequence. ... To date, research into epigenetics has been largely focused on cancer, but the collaborators believe it houses

  • Biogen buys into Rodin's Alzheimer's candidate Biogen buys into Rodin's Alzheimer's candidate

    And may acquire the epigenetics-focused Massachusetts firm. Biogen has signed a deal with Atlas Venture-backed Rodin Therapeutics that could result in the acquisition of the Alzheimer's disease-focused ... Biogen has its own research programme in

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    The expansion of Alzheimer’s R&D is underpinned by evidence that the disease has a range of drivers, including Abeta, inflammation and epigenetics, that evolve as it progresses. ... And a host of other academic and industry teams are looking at

  • Deal Watch November 2016 Deal Watch November 2016

    licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.

  • Deal Watch January 2016 Deal Watch January 2016

    Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research

  • Deal Watch October 2015 Deal Watch October 2015

    Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).

  • Pharma deals in August 2015 Pharma deals in August 2015

    This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Professor Thomas Cech joins Storm Therapeutics Professor Thomas Cech joins Storm Therapeutics

    mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.

  • Storm Therapeutics bolsters its team Storm Therapeutics bolsters its team

    As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.

  • Rubius Therapeutics strengthens senior team Rubius Therapeutics strengthens senior team

    He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing

  • Paul Stockdale joins Oxford BioDynamics as CFO Paul Stockdale joins Oxford BioDynamics as CFO

    A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics